HIGHLIGHTS
- who: Yu Cui from the University Hospital Mu00fcnster, Germany have published the research work: Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer, in the Journal: (JOURNAL)
- what: The authors therefore evaluated whether endogenous GC at the initiation of ICIs may impair the efficacy of PD-1/PD-L1 inhibitors in patients with advanced or metastatic cancer, and further explored whether endogenous GC levels are associated with circulating and tumor-infiltrating T_cell subpopulations, and cytokine secretion. The study reports a comprehensive picture of the negative systemic immunomodulatory effects of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.